Education
About Us
Working with TipRanks
Follow Us
Acarix AB (SE:ACARIX)
:ACARIX
ACARIX Stock Chart & Stats
kr0.28
>-kr0.01(-3.04%)
At close: 4:00 PM EST
kr0.28
>-kr0.01(-3.04%)
Day’s Range― - ―
52-Week Rangekr0.19 - kr0.47
Previous CloseN/A
Volume265.37K
Average Volume (3M)1.57M
Market Cap
kr292.62M
Enterprise Valuekr289.52M
Total Cash (Recent Filing)kr18.27M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta-0.50
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,123,320,200
10 Day Avg. Volume1,780,482
30 Day Avg. Volume1,572,056
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)7.91
Price to Sales (P/S)41.02
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr26.90M
Bulls Say, Bears Say
Bulls Say
Non-invasive Diagnostic ProductCADScor is an algorithm-based, non-invasive diagnostic for ruling out CAD, addressing a persistent clinical need. This structural product fit supports durable demand from providers seeking lower-risk, outpatient-friendly diagnostics and underpins long-term clinical adoption potential.
Installed-base Recurring RevenueThe commercial model pairs capital device sales with single-use consumables, creating an installed-base revenue stream. As device deployments grow, recurring per-test consumable sales can scale revenue and improve unit economics, offering a durable pathway to margin expansion.
Low Financial LeverageTotal debt is effectively zero across recent years, reducing solvency and interest-rate risks. Low leverage provides the company with strategic flexibility and time to scale or pursue partnerships without material fixed debt burdens, a lasting balance-sheet strength.
Bears Say
Very Large Operating LossesOperating losses vastly exceed current revenue, reflecting a structural cost-revenue mismatch. Sustained large negative EBIT indicates the business model has yet to reach scale; without material revenue growth or cost reduction, losses will continue to pressure long-term viability.
Declining Equity / Balance-sheet ErosionEquity has fallen materially over several years, evidencing cumulative losses that erode the capital base. A shrinking equity buffer reduces shock absorption, limits financing options, and increases strategic vulnerability unless profitability or financing sources improve.
Weak Cash Generation; Funding RelianceOperating and free cash flow remain persistently negative and closely track net losses, meaning the company cannot self-fund growth. This structural reliance on external financing creates ongoing dilution risk and constrains long-term strategic independence.
Acarix AB News
ACARIX FAQ
What was Acarix AB’s price range in the past 12 months?
Acarix AB lowest stock price was kr0.19 and its highest was kr0.47 in the past 12 months.
What is Acarix AB’s market cap?
Acarix AB’s market cap is kr292.62M.
When is Acarix AB’s upcoming earnings report date?
Acarix AB’s upcoming earnings report date is May 20, 2026 which is in 75 days.
How were Acarix AB’s earnings last quarter?
Acarix AB released its earnings results on Feb 12, 2026. The company reported -kr0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.01.
Is Acarix AB overvalued?
According to Wall Street analysts Acarix AB’s price is currently Overvalued.
Does Acarix AB pay dividends?
Acarix AB does not currently pay dividends.
What is Acarix AB’s EPS estimate?
Acarix AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Acarix AB have?
Acarix AB has 1,123,320,200 shares outstanding.
What happened to Acarix AB’s price movement after its last earnings report?
Acarix AB reported an EPS of -kr0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.649%.
Which hedge fund is a major shareholder of Acarix AB?
Currently, no hedge funds are holding shares in SE:ACARIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Acarix AB
Acarix AB (publ), a medical technology company, develops and commercializes diagnostic tests for cardiovascular diseases in Germany, Sweden, the Middle East, Switzerland, Austria, and internationally. The company offers CADScor System, a non-invasive and ultra-sensitive analytical device for the diagnosis of coronary artery disease. Acarix AB (publ) was founded in 2009 and is headquartered in Malmö, Sweden.